Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV.

Mazzitelli MariaLolita SassetSamuele GardinDavide LeoniMattia TrunfioVincenzo ScaglioneDaniele MengatoElena AgostiniEleonora VaniaCristina PutaggioAnna Maria Cattelan

Published in: Viruses (2023)

This is the first study on DTG/3TC in PLWH ≥ 65 with a follow-up longer than 5 years. DTG/3TC was found to be safe and effective, neutral on metabolic parameters, and with a low discontinuation rate for toxicity or VF.

Keyphrases

hiv infected patients
gold nanoparticles
oxidative stress
antiretroviral therapy
stem cells
cell therapy
silver nanoparticles